Yüksel Ürün: As a GU oncologist my non-GU key highlights from ASCO24
Yüksel Ürün shared on X/Twitter:
“As a GU oncologist my non-GU key highlights from ASCO24.
1. LAURA:LBA4: Unresectable Stage III EGFR-Mutated NSCLC:
Suresh S. Ramalingam, Winship Cancer Institute of Emory University
- Adjuvant osimertinib vs. placebo after definitive chemoradiation.
- mPFS: 39 months (OSI) vs. 5.6 months (placebo).
- 2-year PFS: 65% (OSI) vs. 13% (placebo).
2. CROWN: LBA8503 Advanced ALK+ NSCLC: Ben Solomon, Peter Mac Cancer Center.
- Lorlatinib vs. crizotinib
- 5-year PFS: 60% (lorlatinib) vs. 8% (crizotinib).
3. ADRIATIC: LBA5 Limited SCLC: David R. Spigel, Sarah Cannon Cancer Institute.
- Adjuvant durvalumab vs. placebo post-chemo radiotherapy
- mPFS: 16 months (D) vs. 9 months (placebo)
- mOS: 55 months (D) vs. 33 months (placebo)
4. ESOPEC: LBA1: Locally Advanced GEJ Adenocarcinoma: J.Hoepner, Bielefeld University.
- Periop chemotherapy (FLOT) vs. preop CRT (CROSS)
- mOS: 66 months (FLOT) vs. 37 months (CROSS)
- 3-year OS: 57% (FLOT) vs. 50% (CROSS)
5. NADINA: LBA2: Stage III Melanoma: Christian U. Blank of The Netherlands Cancer Institute.
- Neoadjuvant NIVO + IPI vs. adjuvant NIVO
- 12-month EFS: 83% (neoadj) vs. 57% (adjuvant)
6. Destiny Breast 06: LBA100 HR+ Metastatic Breast Cancer: Giuseppe Curigliano.
- T-DXd vs. chemotherapy
- mPFS: 13 months (T-DXd) vs. 8 months (chemo)
- ORR: 57% (T-DXd) vs. 32% (chemo).”
Source: Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023